Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016-Reference-Cited by-同舟云学术

Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016

Published:2018-07-01 Issue:7 Volume:4 Page:993
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Zettler Marjorie¹,Nabhan Chadi¹

Affiliation:

1. Cardinal Health Specialty Solutions, Cardinal Health, Dublin, Ohio

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference3 articles.

1. The trade-off between speed and safety in drug approvals.;Jena;JAMA Oncol,2017

2. The fate of FDA postapproval studies.;Woloshin;N Engl J Med,2017

3. US Government Accountability Office. DRUG SAFETY: FDA Expedites Many Applications, But Data for Postapproval Oversight Need Improvement (GAO-16-192: Published December 15, 2015. Publicly released January 14, 2016.) https://www.gao.gov/products/GAO-16-192. Accessed February 27, 2018.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery;Journal of Nanobiotechnology;2024-09-10

2. Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development;Clinical Pharmacology in Drug Development;2024-08-20

3. Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions;Pediatric Drugs;2024-08-05

4. Optimizing the doses of cancer drugs after usual dose finding;Clinical Trials;2023-12-27

5. A descriptive analysis of postmarketing requirement studies and clinical trials;Pharmacoepidemiology and Drug Safety;2023-11-23